Cai Q, Sahu R, Ueberschlag-Pitiot V, Souali-Crespo S, Charvet C, Silem I, Cottard F, Ye T, Taleb F, Metzger E, Schuele R, Billas IML, Laverny G, Metzger D, Duteil D

Nat Commun. 2024 04 26;15(1):3563

KMT9 Controls Stemness and Growth of Colorectal Cancer.

Berlin C, Cottard F, Willmann D, Urban S, Tirier SM, Marx L, Rippe K, Schmitt M, Petrocelli V, Greten FR, Fichtner-Feigl S, Kesselring R, Metzger E, Schüle R

Cancer Res. 2022 01 15;82(2):210-220

Androgen receptor-mediated transcriptional repression targets cell plasticity in prostate cancer.

Erdmann É, Ould Madi Berthélémy P, Cottard F, Angel CZ, Schreyer E, Ye T, Morlet B, Negroni L, Kieffer B, Céraline J

Mol Oncol. 2021 Dec 17;:

KMT9 monomethylates histone H4 lysine 12 and controls proliferation of prostate cancer cells.

Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, Ulferts S, Preca BT, Hermann B, Maurer J, Greschik H, Hornung V, Einsle O, Perner S, Imhof A, Jung M, Schüle R

Nat Struct Mol Biol. 2019 05;26(5):361-371

Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.

Cottard F, Madi-Berthélémy PO, Erdmann E, Schaff-Wendling F, Keime C, Ye T, Kurtz JE, Céraline J

Oncotarget. 2017 Sep 22;8(42):72008-72020

Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.

Cottard F, Ould Madi-Berthélémy P, Erdmann E, Schaff-Wendling F, Keime C, Ye T, Kurtz JE, Céraline J

Oncotarget. 2017 May;:

Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells.

Cottard F, Asmane I, Erdmann E, Bergerat JP, Kurtz JE, Ceraline J

PLoS One. 2013 May 2;8(5):e63466